程序性死亡配体1表达与十种罕见晚期癌症患者预后的关联
Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers.
作者信息
Steiniche Torben, Ladekarl Morten, Georgsen Jeanette Bæhr, Andreasen Simon, Busch-Sørensen Michael, Zhou Wei, Marton Matthew J, Pruitt Scott K, Jin Fan, Liaw Kai-Li
机构信息
Institute of Pathology, Aarhus University Hospital, Aarhus DK-8200, Denmark.
Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
出版信息
Future Sci OA. 2020 Aug 19;6(8):FSO616. doi: 10.2144/fsoa-2020-0063.
AIM
PD-L1 expression and high levels of microsatellite instability (MSI-H) may predict response to checkpoint inhibitors, but their prevalence and prognostic value are unknown in many cancers.
METHODS
We retrospectively evaluated PD-L1 combined positive score (CPS) and MSI-H and their association with clinical outcomes among patients with ten advanced uncommon cancers.
RESULTS
398 of 426 patients (93%) had a valid PD-L1 result; most (242; 61%) had CPS ≥1. Prevalence of MSI-H tumors was 8/360. Median overall survival was shorter among patients with PD-L1 CPS ≥1 tumors after first-line treatment (23.0 vs 39.7 months, p = 0.014).
CONCLUSION
PD-L1 was commonly expressed in solid tumors, and CPS ≥1 was associated with shorter overall survival. Prevalence of MSI-H was low.
目的
程序性死亡受体配体1（PD-L1）表达和高水平微卫星不稳定性（MSI-H）可能预测对检查点抑制剂的反应，但在许多癌症中，它们的发生率和预后价值尚不清楚。
方法
我们回顾性评估了10种晚期罕见癌症患者中PD-L1联合阳性评分（CPS）和MSI-H及其与临床结局的关联。
结果
426例患者中有398例（93%）获得了有效的PD-L1检测结果；大多数（242例；61%）的CPS≥1。MSI-H肿瘤的发生率为8/360。一线治疗后，PD-L1 CPS≥1的肿瘤患者的总生存期较短（23.0个月对39.7个月，p = 0.014）。
结论
PD-L1在实体瘤中普遍表达，CPS≥1与较短的总生存期相关。MSI-H的发生率较低。
Zotero 插件